In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...

A study by Strangfeld et al. adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-TNF antibody treatment, and raises the question of whether live ...

Higher concentrations of anti-TNF agents at the end of the induction period at week 14 were associated with lower risk for lost treatment response. For infliximab, each 10-fold increase in drug ...

The study compared overall deaths, and deaths due to cancer, among patients using TNF inhibitors vs. those on conventional synthetic disease-modifying anti-rheumatic drugs. The researchers ...

Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform ...

Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

Infliximab works by blocking a molecule called tumor necrosis factor (TNF), which is a major part of the body’s immune ...

In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical ...